MedTrace Logo

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

NCT04561518 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-03-31

No results posted yet for this study

Summary

The purpose of this study is to:

* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
* Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting
* Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Conditions

  • Transthyretin-Mediated Amyloidosis
  • ATTR Amyloidosis

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Alnylam Pharmaceuticals

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-23
Primary Completion
2030-09-01
Completion
2030-09-01

Countries

  • United States
  • Brazil
  • Bulgaria
  • Denmark
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04561518 on ClinicalTrials.gov